Clover Announces Positive Phase 2 Clinical Data for RSV + hMPV ± PIV3 Respiratory Combination Vaccine Candidates in Older Adults

Clover Announces Positive Phase 2 Clinical Data for RSV + hMPV ± PIV3 Respiratory Combination Vaccine Candidates in Older Adults

- Positive Phase 2 (Australia) results strengthen potential best-in-class profile of RSV+hMPV±PIV3 combination vaccines, with the potential differentiated...

Clover’s respiratory combo vaccines secure Phase II wins in elderly recipients

Clover Biopharmaceuticals' combination vaccines for respiratory diseases have posted positive data during a Phase II trial in older recipients – a development the Chinese biotech says could highlight its "best-in-class" protective capacity. In the multi-centre mid-stage study, which was conducted…

Clover reports positive Phase 2 respiratory combination vaccine trial in adults

Clover Biopharmaceuticals announced positive Phase 2 clinical trial results in Australia for its combination vaccine candidates targeting respiratory syncytial virus and human metapneumovirus in older adults.